These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

488 related items for PubMed ID: 25418147

  • 1. [Glucagon-like peptide-1 (GLP-1) mimetics: a new treatment for Alzheimer's disease?].
    García-Casares N, García-Arnés JA, Gómez-Huelgas R, Valdivielso-Felices P, García-Arias C, González-Santos P.
    Rev Neurol; 2014 Dec 01; 59(11):517-24. PubMed ID: 25418147
    [Abstract] [Full Text] [Related]

  • 2. Drugs developed for treatment of diabetes show protective effects in Alzheimer's and Parkinson's diseases.
    Hölscher C.
    Sheng Li Xue Bao; 2014 Oct 25; 66(5):497-510. PubMed ID: 25331995
    [Abstract] [Full Text] [Related]

  • 3. Crosstalk between diabetes and brain: glucagon-like peptide-1 mimetics as a promising therapy against neurodegeneration.
    Duarte AI, Candeias E, Correia SC, Santos RX, Carvalho C, Cardoso S, Plácido A, Santos MS, Oliveira CR, Moreira PI.
    Biochim Biophys Acta; 2013 Apr 25; 1832(4):527-41. PubMed ID: 23314196
    [Abstract] [Full Text] [Related]

  • 4. Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's disease.
    Holscher C.
    Recent Pat CNS Drug Discov; 2010 Jun 25; 5(2):109-17. PubMed ID: 20337586
    [Abstract] [Full Text] [Related]

  • 5. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems.
    Seufert J, Gallwitz B.
    Diabetes Obes Metab; 2014 Aug 25; 16(8):673-88. PubMed ID: 24373150
    [Abstract] [Full Text] [Related]

  • 6. Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases.
    Hölscher C.
    J Endocrinol; 2014 Apr 25; 221(1):T31-41. PubMed ID: 23999914
    [Abstract] [Full Text] [Related]

  • 7. Targeting amyloid-beta by glucagon-like peptide -1 (GLP-1) in Alzheimer's disease and diabetes.
    Bak AM, Egefjord L, Gejl M, Steffensen C, Stecher CW, Smidt K, Brock B, Rungby J.
    Expert Opin Ther Targets; 2011 Oct 25; 15(10):1153-62. PubMed ID: 21749267
    [Abstract] [Full Text] [Related]

  • 8. [Impact of anti-diabetic therapy based on glucagon-like peptide-1 receptor agonists on the cardiovascular risk of patients with type 2 diabetes mellitus].
    Camafort-Babkowski M.
    Med Clin (Barc); 2013 Aug 17; 141(4):167-74. PubMed ID: 23332622
    [Abstract] [Full Text] [Related]

  • 9. Neuroprotective and restorative properties of the GLP-1/GIP dual agonist DA-JC1 compared with a GLP-1 single agonist in Alzheimer's disease.
    Salles GN, Calió ML, Hölscher C, Pacheco-Soares C, Porcionatto M, Lobo AO.
    Neuropharmacology; 2020 Jan 01; 162():107813. PubMed ID: 31628935
    [Abstract] [Full Text] [Related]

  • 10. [Glucagon-like peptide 1: a novel therapeutic strategy for Alzheimer's disease].
    Wang XH, Yang W, Qi JS.
    Sheng Li Xue Bao; 2010 Oct 25; 62(5):398-406. PubMed ID: 20945041
    [Abstract] [Full Text] [Related]

  • 11. Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease.
    Hölscher C.
    Biochem Soc Trans; 2011 Aug 25; 39(4):891-7. PubMed ID: 21787319
    [Abstract] [Full Text] [Related]

  • 12. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease.
    McClean PL, Hölscher C.
    Neuropharmacology; 2014 Jan 25; 76 Pt A():57-67. PubMed ID: 23973293
    [Abstract] [Full Text] [Related]

  • 13. The glucagon-like peptides: a new genre in therapeutic targets for intervention in Alzheimer's disease.
    Perry T, Greig NH.
    J Alzheimers Dis; 2002 Dec 25; 4(6):487-96. PubMed ID: 12515900
    [Abstract] [Full Text] [Related]

  • 14. Therapies for inter-relating diabetes and obesity - GLP-1 and obesity.
    Iepsen EW, Torekov SS, Holst JJ.
    Expert Opin Pharmacother; 2014 Dec 25; 15(17):2487-500. PubMed ID: 25260877
    [Abstract] [Full Text] [Related]

  • 15. Antidiabetic agents as a novel treatment for Alzheimer's and Parkinson's disease.
    Nowell J, Blunt E, Gupta D, Edison P.
    Ageing Res Rev; 2023 Aug 25; 89():101979. PubMed ID: 37328112
    [Abstract] [Full Text] [Related]

  • 16. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M, Harris K, Brackett A.
    Ann Pharmacother; 2012 Jan 25; 46(1):68-78. PubMed ID: 22232377
    [Abstract] [Full Text] [Related]

  • 17. GLP-1 receptor agonists for type 2 diabetes.
    De Block CE, Van Gaal LF.
    Lancet; 2009 Jul 04; 374(9683):4-6. PubMed ID: 19515414
    [No Abstract] [Full Text] [Related]

  • 18. Emerging GLP-1 receptor agonists.
    Lund A, Knop FK, Vilsbøll T.
    Expert Opin Emerg Drugs; 2011 Dec 04; 16(4):607-18. PubMed ID: 21905764
    [Abstract] [Full Text] [Related]

  • 19. A New Treatment Strategy for Parkinson's Disease through the Gut-Brain Axis: The Glucagon-Like Peptide-1 Receptor Pathway.
    Kim DS, Choi HI, Wang Y, Luo Y, Hoffer BJ, Greig NH.
    Cell Transplant; 2017 Sep 04; 26(9):1560-1571. PubMed ID: 29113464
    [Abstract] [Full Text] [Related]

  • 20. Incretin hormone mimetics and analogues in diabetes therapeutics.
    Green BD, Flatt PR.
    Best Pract Res Clin Endocrinol Metab; 2007 Dec 04; 21(4):497-516. PubMed ID: 18054732
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.